Osteosarcoma Multi-Omics Landscape and Subtypes

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Oct 28

PMID 37894336

Authors

Shan Tang

Ryan D Roberts

Lijun Cheng

Lang Li

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) is the most common primary bone malignancy that exhibits remarkable histologic diversity and genetic heterogeneity. The complex nature of osteosarcoma has confounded precise molecular categorization, prognosis, and prediction for this disease. In this study, we performed a comprehensive multiplatform analysis on 86 osteosarcoma tumors, including somatic copy-number alteration, gene expression and methylation, and identified three molecularly distinct and clinically relevant subtypes of osteosarcoma. The subgrouping criteria was validated on another cohort of osteosarcoma tumors. Previously unappreciated osteosarcoma-type-specific changes in specific genes' copy number, expression and methylation were revealed based on the subgrouping. The subgrouping and novel gene signatures provide insights into refining osteosarcoma therapy and relationships to other types of cancer.

Citing Articles

Whole-Exome Analysis and Osteosarcoma: A Game Still Open.

Chiappetta C, Della Rocca C, Di Cristofano C Int J Mol Sci. 2025; 25(24.

PMID: 39769419 PMC: 11728052. DOI: 10.3390/ijms252413657.

MTF2 facilitates the advancement of osteosarcoma through mediating EZH2/SFRP1/Wnt signaling.

Hu X, Liu Y, Shen H, Zhang T, Liang T J Orthop Surg Res. 2024; 19(1):467.

PMID: 39118123 PMC: 11312803. DOI: 10.1186/s13018-024-04965-9.

References

Lee K, Kim H, Jang M, Lee S, Ahn S, Park S . Centromere 17 copy number gain reflects chromosomal instability in breast cancer. Sci Rep. 2019; 9(1):17968. PMC: 6884473. DOI: 10.1038/s41598-019-54471-w. View

Wang Z, Wang Y, Peng M, Yi L . UBASH3B Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Prostate Cancer. Front Oncol. 2020; 9:1517. PMC: 6974685. DOI: 10.3389/fonc.2019.01517. View

Kuijjer M, Rydbeck H, Kresse S, Buddingh E, Lid A, Roelofs H . Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data. Genes Chromosomes Cancer. 2012; 51(7):696-706. DOI: 10.1002/gcc.21956. View

Misaghi A, Goldin A, Awad M, Kulidjian A . Osteosarcoma: a comprehensive review. SICOT J. 2018; 4:12. PMC: 5890448. DOI: 10.1051/sicotj/2017028. View

Yang G, Yuan J, Li K . EMT transcription factors: implication in osteosarcoma. Med Oncol. 2013; 30(4):697. DOI: 10.1007/s12032-013-0697-2. View

Cheng H, Qin Y, Fan H, Su P, Zhang X, Zhang H . Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes. Diagn Pathol. 2013; 8:129. PMC: 3766166. DOI: 10.1186/1746-1596-8-129. View

Wang D, Bao H . Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6-Cyclin D-Rb pathway. Cancer Chemother Pharmacol. 2021; 89(1):31-40. DOI: 10.1007/s00280-021-04363-6. View

Greenblatt S, Man N, Hamard P, Asai T, Karl D, Martinez C . CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. Cancer Cell. 2018; 33(6):1111-1127.e5. PMC: 6191185. DOI: 10.1016/j.ccell.2018.05.007. View

Bergstrand S, Bohm S, Malmgren H, Norberg A, Sundin M, Nordgren A . Biallelic mutations in WRAP53 result in dysfunctional telomeres, Cajal bodies and DNA repair, thereby causing Hoyeraal-Hreidarsson syndrome. Cell Death Dis. 2020; 11(4):238. PMC: 7165179. DOI: 10.1038/s41419-020-2421-4. View

10.

Lin C, Chen J, Lin M, Chan C, Wen Y, Wu S . Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance. Toxicol Appl Pharmacol. 2015; 288(3):359-73. DOI: 10.1016/j.taap.2015.08.008. View

11.

Chen D, Zhao Z, Huang Z, Chen D, Zhu X, Wang Y . Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. Bone Res. 2018; 6:11. PMC: 5884797. DOI: 10.1038/s41413-018-0009-8. View

12.

Martin J, Squire J, Zielenska M . The genetics of osteosarcoma. Sarcoma. 2012; 2012:627254. PMC: 3364016. DOI: 10.1155/2012/627254. View

13.

Mahmoudi S, Henriksson S, Farnebo L, Roberg K, Farnebo M . WRAP53 promotes cancer cell survival and is a potential target for cancer therapy. Cell Death Dis. 2011; 2:e114. PMC: 3077286. DOI: 10.1038/cddis.2010.90. View

14.

Lin J, Liu H, Fukumoto T, Zundell J, Yan Q, Tang C . Targeting the IRE1α/XBP1s pathway suppresses CARM1-expressing ovarian cancer. Nat Commun. 2021; 12(1):5321. PMC: 8423755. DOI: 10.1038/s41467-021-25684-3. View

15.

Varshney J, Scott M, Largaespada D, Subramanian S . Understanding the Osteosarcoma Pathobiology: A Comparative Oncology Approach. Vet Sci. 2017; 3(1). PMC: 5644613. DOI: 10.3390/vetsci3010003. View

16.

Padovan-Merhar O, Nair G, Biaesch A, Mayer A, Scarfone S, Foley S . Single mammalian cells compensate for differences in cellular volume and DNA copy number through independent global transcriptional mechanisms. Mol Cell. 2015; 58(2):339-52. PMC: 4402149. DOI: 10.1016/j.molcel.2015.03.005. View

17.

Katoh M . WNT/PCP signaling pathway and human cancer (review). Oncol Rep. 2005; 14(6):1583-8. View

18.

Spainhour J, Lim H, Yi S, Qiu P . Correlation Patterns Between DNA Methylation and Gene Expression in The Cancer Genome Atlas. Cancer Inform. 2019; 18:1176935119828776. PMC: 6376553. DOI: 10.1177/1176935119828776. View

19.

Krupina K, Kleiss C, Awal S, Rodriguez-Hernandez I, Sanz-Moreno V, Sumara I . UBASH3B-mediated silencing of the mitotic checkpoint: Therapeutic perspectives in cancer. Mol Cell Oncol. 2018; 5(2):e1271494. PMC: 5821415. DOI: 10.1080/23723556.2016.1271494. View

20.

Wu D, He J, Zhang W, Wang K, Jin S, Li J . CARM1 promotes non-small cell lung cancer progression through upregulating CCNE2 expression. Aging (Albany NY). 2020; 12(11):10578-10593. PMC: 7346078. DOI: 10.18632/aging.103280. View